Clinical Trial Update: TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial update for TEMCAP in grade 3 and low Ki-67 gastroenteropancreatic neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumors
• Neuroendocrine Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• TEMCAP
• Temozolomide (Temozolomide)

Snippet

Sponsor: Asan Medical Center | Conditions: Neuroendocrine Tumors, Neuroendocrine Carcinoma | Phase 2 | Status: COMPLETED